RecruitingNCT07683065

A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

SEC-HOPE: A Multicenter Retrospective Cohort Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

Sponsor

Novartis Pharmaceuticals

Enrollment

150 participants

Start Date

Jul 8, 2026

Study Type

OBSERVATIONAL

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease Plaque Psoriasis

Summary

This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \[PsA\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with metabolic dysfunction-associated steatotic liver disease and plaque psoriasis. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.